TWD 76.9
(-9.95%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 6.03 Million TWD | -0.87% |
2022 | 6.08 Million TWD | -22.23% |
2021 | 7.82 Million TWD | 15.22% |
2020 | 6.79 Million TWD | 102.83% |
2019 | -240.1 Million TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 15.25 Million TWD | 0.0% |
2024 Q2 | 24.02 Million TWD | 0.0% |
2023 Q4 | 6.03 Million TWD | 17.16% |
2023 FY | 6.03 Million TWD | -0.87% |
2023 Q3 | 5.15 Million TWD | -15.72% |
2023 Q2 | 6.11 Million TWD | 17.63% |
2023 Q1 | 5.19 Million TWD | 102.28% |
2022 FY | 6.08 Million TWD | -22.23% |
2022 Q4 | -227.79 Million TWD | 0.0% |
2021 FY | 7.82 Million TWD | 15.22% |
2020 FY | 6.79 Million TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
DIVA Laboratories, Ltd. | - TWD | -Infinity% |
Genetics Generation Advancement Corp. | 10.34 Million TWD | 41.653% |
Welgene Biotech Co.,Ltd. | 118.97 Million TWD | 94.926% |
Puriblood Medical Co., Ltd. | 43.7 Million TWD | 86.188% |
TFBS Bioscience Inc. | 101.84 Million TWD | 94.073% |